Episódios

  • Long-Term Outcomes and Rehabilitation in Anti-NMDAR Encephalitis - Part 1

    Long-Term Outcomes and Rehabilitation in Anti-NMDAR Encephalitis - Part 1
    Nov 22 2024

    In part one of this two-part series, Dr. Justin Abbatemarco and Dr. Maarten Titulaer discuss long-term cognitive and functional outcomes in patients with anti-NMDAR encephalitis and their implications for rehabilitation.

    Show reference:

    https://www.neurology.org/doi/pdf/10.1212/WNL.0000000000210109
    Exibir mais Exibir menos
    2 minutos
  • Myelitis Associated With Rheumatologic Disease - Part 2

    Myelitis Associated With Rheumatologic Disease - Part 2
    Nov 21 2024

    In part two of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss abandoning the term lupus myelitis and emphasize the importance of accurately naming and identifying each autoimmune condition.

    Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200329

    Exibir mais Exibir menos
    3 minutos
  • Myelitis Associated With Rheumatologic Disease - Part 1

    Myelitis Associated With Rheumatologic Disease - Part 1
    Nov 20 2024

    In part one of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss key features of inflammatory myelopathy in rheumatologic disease, helping to better characterize the underlying causes of lupus myelitis.

    Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200329

    Exibir mais Exibir menos
    5 minutos
  • Could GLP-1 Receptor Agonists Reduce the Risk of Neurologic Disorders?

    Could GLP-1 Receptor Agonists Reduce the Risk of Neurologic Disorders?
    Nov 19 2024

    Dr. Tesha Monteith discusses the Brain & Life article, “Could GLP-1 Receptor Agonists Reduce the Risk of Neurologic Disorders?” by Hallie Levine, available in the latest issue of Brain & Life or at brainandlife.org.

    Show reference:

    https://www.brainandlife.org/articles/new-weight-loss-drugs-may-help-neurologic-disorders

    Exibir mais Exibir menos
    2 minutos
  • CAA-RI and Biopsy-Positive Primary Angiitis of the CNS - Part 3

    CAA-RI and Biopsy-Positive Primary Angiitis of the CNS - Part 3
    Nov 18 2024

    In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how to differentiate between CAA-RI and PACNS.

    Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548

    Exibir mais Exibir menos
    2 minutos
  • The Placebo Effect

    The Placebo Effect
    Nov 15 2024

    Dr. Gregg Day and Dr. Kathryn T. Hall discuss the complexities of the placebo effect, its variability among patients, and the genetic factors that influence responses to placebo treatments.

    Exibir mais Exibir menos
    1 minuto
  • CAA-RI and Biopsy-Positive Primary Angiitis of the CNS - Part 2

    CAA-RI and Biopsy-Positive Primary Angiitis of the CNS - Part 2
    Nov 14 2024

    In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss the underlying pathophysiology and how to diagnose primary angiitis of the CNS in clinical practice.

    Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548

    Exibir mais Exibir menos
    2 minutos
  • CAA-RI and Biopsy-Positive Primary Angiitis of the CNS - Part 1

    CAA-RI and Biopsy-Positive Primary Angiitis of the CNS - Part 1
    Nov 13 2024

    In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how cerebral amyloid angiopathy and CAA-RI present in clinical practice and how to make a diagnosis.

    Show reference:

    https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548

    Exibir mais Exibir menos
    2 minutos